Detalhe da pesquisa
1.
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
N Engl J Med
; 388(3): 228-239, 2023 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652354
2.
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
J Hepatol
; 80(2): 322-334, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37972659
3.
A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations.
Future Oncol
; 18(30): 3377-3387, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36039910
4.
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.
Invest New Drugs
; 31(4): 1016-22, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23417696
5.
A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.
Cancer
; 118(21): 5403-13, 2012 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22570147
6.
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.
NPJ Breast Cancer
; 7(1): 57, 2021 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34016993
7.
Do We have a Satisfactory Cell Viability Assay? Review of the Currently Commercially-Available Assays.
Curr Drug Discov Technol
; 17(1): 2-22, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-30251606
8.
Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics.
Ann N Y Acad Sci
; 1346(1): 63-70, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25758153
9.
Preservation of human pancreatic islet in vivo function after 6-month culture in serum-free media.
Transplantation
; 77(8): 1147-54, 2004 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-15114076
10.
The biggest challenges currently facing companion diagnostic advancement.
Expert Rev Mol Diagn
; 14(1): 27-35, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24308333
11.
Ex vivo reversal of the anticoagulant effects of edoxaban.
Thromb Res
; 134(4): 909-13, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25179520
12.
Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment.
J Clin Pharmacol
; 54(8): 910-6, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24706516
13.
Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
Clin Cancer Res
; 19(11): 3078-87, 2013 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23591447
14.
Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.
Thromb Haemost
; 108(1): 166-75, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22628060
15.
Discrepant results from laboratories impact patients receiving heparin or antithrombin therapy.
Biomark Med
; 5(2): 211-8, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21473726
16.
Impact of discrepant results from clinical laboratories on patients and pharmaceutical trials: evidence from proficiency testing results.
Biomark Med
; 3(3): 231-8, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20477475